Cargando…

Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies

INTRODUCTION: Immuno-oncology therapies, including immune checkpoint inhibitors (ICIs), have transformed cancer care and have brought into question whether classic oncology efficacy assessments adequately describe the distinctive responses observed with these agents. With more ICI-based therapies be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michielin, Olivier, Lalani, Aly-Khan, Robert, Caroline, Sharma, Padmanee, Peters, Solange
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796265/ https://www.ncbi.nlm.nih.gov/pubmed/35078922 http://dx.doi.org/10.1136/jitc-2021-003024

Ejemplares similares

Correction: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Publicado: (2022)

Hallmarks of Resistance to Immune-Checkpoint Inhibitors
por: Karasarides, Maria, et al.
Publicado: (2022)

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
por: Kim, Sang T., et al.
Publicado: (2022)

Hallmarks of response to immune checkpoint blockade
por: Cogdill, Alexandria P, et al.
Publicado: (2017)

(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
por: Boughdad, Sarah, et al.
Publicado: (2021)

Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events
por: Coukos, Alexander, et al.
Publicado: (2022)

A decade of immune-checkpoint inhibitors in cancer therapy
por: Robert, Caroline
Publicado: (2020)

Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma
por: Angell, Trevor E., et al.
Publicado: (2017)

Immune checkpoint inhibitor in liver cancer—unique regional differences
por: Obi, Shuntaro, et al.
Publicado: (2020)

Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors
por: Brocco, Davide, et al.
Publicado: (2021)

Acute cardiac manifestations under immune checkpoint inhibitors—beware of the obvious: a case report
por: Arangalage, Dimitri, et al.
Publicado: (2021)

Spatial and temporal localization of immune transcripts defines hallmarks and diversity in the tuberculosis granuloma
por: Carow, Berit, et al.
Publicado: (2019)

Neutrophils in the era of immune checkpoint blockade
por: Faget, Julien, et al.
Publicado: (2021)

Interferon-Gamma–Producing CD8(+) Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis
por: Sasson, Sarah C., et al.
Publicado: (2021)

Immune checkpoint inhibitors in cancer therapy
por: Webb, Eika S., et al.
Publicado: (2018)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
por: Quilez, Alicia, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Cancer Therapy
por: Shiravand, Yavar, et al.
Publicado: (2022)

The side effects of immune checkpoint inhibitor therapy on the endocrine system
por: Goyal, Itivrita, et al.
Publicado: (2021)

Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy
por: Hailemichael, Yared, et al.
Publicado: (2014)

Immune Checkpoint Inhibitor Therapy Associated Hypophysitis
por: Mahzari, Moeber, et al.
Publicado: (2015)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
por: Lee, Juwon, et al.
Publicado: (2021)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Immune checkpoint inhibitor therapy for hepatocellular carcinoma
por: Ramai, Daryl, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
por: Gubbi, Sriram, et al.
Publicado: (2022)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
por: Basudan, Ahmed M.
Publicado: (2022)

Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors
por: Drobni, Zsofia D., et al.
Publicado: (2022)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)

Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma
por: Melin, Audrey, et al.
Publicado: (2022)

Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy
por: Kuang, Andrew G., et al.
Publicado: (2023)

Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy
por: El Kawkgi, Omar M., et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies
por: Maung, Tun Zan, et al.
Publicado: (2020)

Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy
por: Zurko, Joanna, et al.
Publicado: (2018)

Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma
por: Sharma, Rohini, et al.
Publicado: (2021)

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
por: Haanen, John, et al.
Publicado: (2020)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

2011: the immune hallmarks of cancer
por: Cavallo, Federica, et al.
Publicado: (2011)

Hypothyroidism After Use of Immune Checkpoint Inhibitor Therapy in Patient With Graves' Disease: Cure?
por: Sharma, Rajeev
Publicado: (2022)

Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy
por: Balakrishna, Pragathi, et al.
Publicado: (2017)

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
por: Botticelli, Andrea, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gvmbeh9thlgmd8vvjg65o1k05p